Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Brittany Emmerson"'
Autor:
Lachlan McIntosh, Price Jackson, Brittany Emmerson, James P. Buteau, Ramin Alipour, Grace Kong, Michael S. Hofman
Publikováno v:
EJNMMI Physics, Vol 11, Iss 1, Pp 1-10 (2024)
Abstract Background Terbium-161 (161Tb)-based radionuclide therapy poses an alternative to current Lutetium-177 (177Lu) approaches with the additional benefit of secondary Auger and conversion electron emissions capable of delivering high doses of lo
Externí odkaz:
https://doaj.org/article/4af472ac353143a988c71298c7ef360f
Autor:
Louise Kostos, James P. Buteau, Theresa Yeung, Juliana Di Iulio, Jing Xie, Anthony Cardin, Kwang Y. Chin, Brittany Emmerson, Katie L. Owen, Belinda S. Parker, Heidi Fettke, Luc Furic, Arun A. Azad, Michael S. Hofman
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Background[177Lu]Lu-PSMA is a radioligand therapy used in metastatic castration-resistant prostate cancer (mCRPC). Despite a survival benefit, the responses for many patients receiving [177Lu]Lu-PSMA are not durable, and all patients eventually devel
Externí odkaz:
https://doaj.org/article/ee75493d95874a12b67e6d0f0cb88f42
Autor:
James Patrick Buteau, Louise Kathleen Kostos, Ramin Alipour, Price Jackson, Lachlan McIntosh, Brittany Emmerson, Mohammad B Haskali, Theresa Yeung, Sophia Xie, Elizabeth Medhurst, Rajeev Ravi, Brian D. Gonzalez, Heidi Fettke, Nicole Ng, Maria Docanto, Patricia Bukczynska, Benjamin Blyth, Luc Furic, Arun Azad, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 41:TPS281-TPS281
TPS281 Background: [177Lu]Lu-PSMA is an effective class of therapy for men with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response is partially explained by the presence of
Autor:
Louise Kathleen Kostos, James Patrick Buteau, Theresa Yeung, Sophia Xie, Juliana Di Iulio, Anthony Cardin, Katie Owen, Heidi Fettke, Kwang Y Chin, Brittany Emmerson, Mohammad B Haskali, Belinda Parker, Luc Furic, Arun Azad, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 41:TPS280-TPS280
TPS280 Background: [177Lu]Lu-PSMA-I&T (LuPSMA) is a small molecule radioligand that delivers radiation via beta-particulate emission to cells expressing prostate-specific membrane antigen (PSMA). Despite a survival benefit in mCRPC, responses for man